抗IgLON-5疾病呈现轴性和对乙胺反应性呼吸暂停
Gwen Zeigler1, Miriam Quinlan1, Panayiotis N Varelas1
1Department of Neurology, Albany Medical Center, 43 New Scotland Ave. MC-70, Albany, NY 12208, USA.
这种病例研究突出显示了抗IgLON5疾病的表现,包括 dystonic和中心低通风. 乙胺有效治疗低通风,这是这种罕见的自身免疫神经疾病的新发现.
科学领域:
- 神经学
- 免疫学
- 睡眠医学
背景情况:
- 抗免疫球蛋白IgLON5 (IgLON5) 疾病是一种罕见的自身免疫性疾病.
- 其中包括运动障碍和睡眠障碍.
研究的目的:
- 报告抗IgLON5疾病的病例与突出的轴性 dystonia 和中心低通风.
- 描述乙胺在这种疾病中治疗中心低通风的新和有效用途.
主要方法:
- 这是一个67岁男性的临床病例.
- 诊断工作包括脑MRI和脑脊液 (CSF) 分析IgLON5抗体.
- 治疗包括免疫疗法 (IVIg,血交换,利图西马布) 和乙胺.
主要成果:
- 患者出现了宫和上半身,幻觉和手.
- 证实了IgLON5抗体的存在.
- 虽然免疫疗法缓解了一些症状,但乙胺有效地缓解了中心低通风的恶化.
- 轴性 dystonia, 具体的 anterocollis, 是一个显著的特征.
结论:
- 轴性可以是抗IgLON5疾病的突出表现.
- 乙胺是一种潜在的治疗抗IgLON5疾病的中心低通风,这标志着其首次用于这种适应症.
更多相关视频
06:04Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
Published on: August 16, 2024
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
相关概念视频
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Antiepileptic Drugs: Glutamate Antagonists
